Durvalumab impacts progression-free survival while high-dose radiation >66 Gy improves local control without excess toxicity in unresectable NSCLC stage III: Real-world data from the Austrian radio-oncological lung cancer study association registry (ALLSTAR).

Zehentmayr, Franz, Feurstein, Petra, Ruznic, Elvis, Langer, Brigitte, Grambozov, Brane, Klebermass, Marisa, Hüpfel, Herbert, Feichtinger, Johann, Minasch, Danijela, Heilmann, Martin, Breitfelder, Barbara, Steffal, Claudia, Gastinger-Grass, Gisela, Kirchhammer, Karoline, Kazil, Margit, Stranzl, Heidi and Dieckmann, Karin (2024) Durvalumab impacts progression-free survival while high-dose radiation >66 Gy improves local control without excess toxicity in unresectable NSCLC stage III: Real-world data from the Austrian radio-oncological lung cancer study association registry (ALLSTAR). Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 196. p. 110294. ISSN 1879-0887

Preview

Text
Feichtinger Durvalumab impacts progression free survival while high-dose radiation 66 Gy improves local control without excess toxicity in unresectable NSCLC stage III Elsevier 2024.pdf - Published Version
Download (1MB) | Preview

Edit Item